A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer

PF 03446962 7 mg/kg, IV, every 2 weeks, until disease progression, patient refusal or unacceptable toxicity, whichever occurs first

BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life

Placebo will consist of Saline (0.9% w/v Sodium Chloride Injection, USP or NS)

BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.